383 related articles for article (PubMed ID: 36873165)
1. Peptide-drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope?
Fu C; Yu L; Miao Y; Liu X; Yu Z; Wei M
Acta Pharm Sin B; 2023 Feb; 13(2):498-516. PubMed ID: 36873165
[TBL] [Abstract][Full Text] [Related]
2. Peptide-drug conjugates: A new paradigm for targeted cancer therapy.
Wang M; Liu J; Xia M; Yin L; Zhang L; Liu X; Cheng Y
Eur J Med Chem; 2024 Feb; 265():116119. PubMed ID: 38194773
[TBL] [Abstract][Full Text] [Related]
3. Peptides as a platform for targeted therapeutics for cancer: peptide-drug conjugates (PDCs).
Cooper BM; Iegre J; O' Donovan DH; Ölwegård Halvarsson M; Spring DR
Chem Soc Rev; 2021 Feb; 50(3):1480-1494. PubMed ID: 33346298
[TBL] [Abstract][Full Text] [Related]
4. Gold nanoparticles stabilize peptide-drug-conjugates for sustained targeted drug delivery to cancer cells.
Kalimuthu K; Lubin BC; Bazylevich A; Gellerman G; Shpilberg O; Luboshits G; Firer MA
J Nanobiotechnology; 2018 Mar; 16(1):34. PubMed ID: 29602308
[TBL] [Abstract][Full Text] [Related]
5. Multivalent protein-drug conjugates - An emerging strategy for the upgraded precision and efficiency of drug delivery to cancer cells.
Porębska N; Ciura K; Chorążewska A; Zakrzewska M; Otlewski J; Opaliński Ł
Biotechnol Adv; 2023 Oct; 67():108213. PubMed ID: 37453463
[TBL] [Abstract][Full Text] [Related]
6. On the design principles of peptide-drug conjugates for targeted drug delivery to the malignant tumor site.
Vrettos EI; Mező G; Tzakos AG
Beilstein J Org Chem; 2018; 14():930-954. PubMed ID: 29765474
[TBL] [Abstract][Full Text] [Related]
7. Peptide-Drug Conjugates: Design, Chemistry, and Drug Delivery System as a Novel Cancer Theranostic.
Rizvi SFA; Zhang L; Zhang H; Fang Q
ACS Pharmacol Transl Sci; 2024 Feb; 7(2):309-334. PubMed ID: 38357281
[TBL] [Abstract][Full Text] [Related]
8. A Review on Exploring the Opportunities of Polymer Drug Conjugated Systems for Targeted Cancer Treatment.
Gupta C; Naik I; Menon M; Ambre P; Coutinho E
Curr Drug Deliv; 2022; 20(1):8-30. PubMed ID: 35400344
[TBL] [Abstract][Full Text] [Related]
9. Learn from antibody-drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy.
Wu M; Huang W; Yang N; Liu Y
Exp Hematol Oncol; 2022 Nov; 11(1):93. PubMed ID: 36348391
[TBL] [Abstract][Full Text] [Related]
10. Progress and Future Directions with Peptide-Drug Conjugates for Targeted Cancer Therapy.
Lindberg J; Nilvebrant J; Nygren PÅ; Lehmann F
Molecules; 2021 Oct; 26(19):. PubMed ID: 34641586
[TBL] [Abstract][Full Text] [Related]
11. Peptide Drug Conjugates and Their Role in Cancer Therapy.
Heh E; Allen J; Ramirez F; Lovasz D; Fernandez L; Hogg T; Riva H; Holland N; Chacon J
Int J Mol Sci; 2023 Jan; 24(1):. PubMed ID: 36614268
[TBL] [Abstract][Full Text] [Related]
12. Antibody-Assisted Delivery of a Peptide-Drug Conjugate for Targeted Cancer Therapy.
Kim H; Hwang D; Choi M; Lee S; Kang S; Lee Y; Kim S; Chung J; Jon S
Mol Pharm; 2019 Jan; 16(1):165-172. PubMed ID: 30521347
[TBL] [Abstract][Full Text] [Related]
13. Drug conjugate-based anticancer therapy - Current status and perspectives.
Yang Y; Wang S; Ma P; Jiang Y; Cheng K; Yu Y; Jiang N; Miao H; Tang Q; Liu F; Zha Y; Li N
Cancer Lett; 2023 Jan; 552():215969. PubMed ID: 36279982
[TBL] [Abstract][Full Text] [Related]
14. Research advances in peptide‒drug conjugates.
Gong L; Zhao H; Liu Y; Wu H; Liu C; Chang S; Chen L; Jin M; Wang Q; Gao Z; Huang W
Acta Pharm Sin B; 2023 Sep; 13(9):3659-3677. PubMed ID: 37719380
[TBL] [Abstract][Full Text] [Related]
15. Molecular Engineering of Peptide-Drug Conjugates for Therapeutics.
Fang Y; Wang H
Pharmaceutics; 2022 Jan; 14(1):. PubMed ID: 35057106
[TBL] [Abstract][Full Text] [Related]
16. Development of programmable gemcitabine-GnRH pro-drugs bearing linker controllable "click" oxime bond tethers and preclinical evaluation against prostate cancer.
Vrettos EI; Karampelas T; Sayyad N; Kougioumtzi A; Syed N; Crook T; Murphy C; Tamvakopoulos C; Tzakos AG
Eur J Med Chem; 2021 Feb; 211():113018. PubMed ID: 33223264
[TBL] [Abstract][Full Text] [Related]
17. The development of peptide-drug conjugates (PDCs) strategies for paclitaxel.
Wang L; Chen H; Wang F; Zhang X
Expert Opin Drug Deliv; 2022 Feb; 19(2):147-161. PubMed ID: 35130795
[TBL] [Abstract][Full Text] [Related]
18. Polymer-drug conjugates: Design principles, emerging synthetic strategies and clinical overview.
Javia A; Vanza J; Bardoliwala D; Ghosh S; Misra LA; Patel M; Thakkar H
Int J Pharm; 2022 Jul; 623():121863. PubMed ID: 35643347
[TBL] [Abstract][Full Text] [Related]
19. Antiviral Peptide-Based Conjugates: State of the Art and Future Perspectives.
Todorovski T; Kalafatovic D; Andreu D
Pharmaceutics; 2023 Jan; 15(2):. PubMed ID: 36839679
[TBL] [Abstract][Full Text] [Related]
20. Advances in targeted therapy for pancreatic cancer.
Xing L; Lv L; Ren J; Yu H; Zhao X; Kong X; Xiang H; Tao X; Dong D
Biomed Pharmacother; 2023 Dec; 168():115717. PubMed ID: 37862965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
